Clinical impact of vivax malaria: A collection review

Aung Pyae Phyoe1, Prabin Dahal2,3, Mayfong Mayxay3,4,5, Elizabeth A. Ashley3,5*

1 Myanmar Oxford Clinical Research Unit, Yangon, Myanmar, 2 Infectious Diseases Data Observatory–IDDO, Oxford, United Kingdom, 3 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 4 Institute of Research and Education Development (IRED), University of Health Sciences, Ministry of Health, Vientiane, Laos, 5 Lao–Oxford–Mahosot Hospital–Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Laos

* liz@tropmedres.ac

Abstract

Background

Plasmodium vivax infects an estimated 7 million people every year. Previously, vivax malaria was perceived as a benign condition, particularly when compared to falciparum malaria. Reports of the severe clinical impacts of vivax malaria have been increasing over the last decade.

Methods and findings

We describe the main clinical impacts of vivax malaria, incorporating a rapid systematic review of severe disease with meta-analysis of data from studies with clearly defined denominators, stratified by hospitalization status. Severe anemia is a serious consequence of relapsing infections in children in endemic areas, in whom vivax malaria causes increased morbidity and mortality and impaired school performance. *P. vivax* infection in pregnancy is associated with maternal anemia, prematurity, fetal loss, and low birth weight. More than 11,658 patients with severe vivax malaria have been reported since 1929, with 15,954 manifestations of severe malaria, of which only 7,157 (45%) conformed to the World Health Organization (WHO) diagnostic criteria. Out of 423 articles, 311 (74%) were published since 2010. In a random-effects meta-analysis of 85 studies, 68 of which were in hospitalized patients with vivax malaria, we estimated the proportion of patients with WHO-defined severe disease as 0.7% [95% confidence interval (CI) 0.19% to 2.57%] in all patients with vivax malaria and 7.11% [95% CI 4.30% to 11.55%] in hospitalized patients. We estimated the mortality from vivax malaria as 0.01% [95% CI 0.00% to 0.07%] in all patients and 0.56% [95% CI 0.35% to 0.92%] in hospital settings. WHO-defined cerebral, respiratory, and renal severe complications were generally estimated to occur in fewer than 0.5% patients in all included studies. Limitations of this review include the observational nature and small size of most of the studies of severe vivax malaria, high heterogeneity of included studies which were predominantly in hospitalized patients (who were therefore more likely to be severely unwell), and high risk of bias including small study effects.
Conclusions
Young children and pregnant women are particularly vulnerable to adverse clinical impacts of vivax malaria, and preventing infections and relapse in this groups is a priority. Substantial evidence of severe presentations of vivax malaria has accrued over the last 10 years, but reporting is inconsistent. There are major knowledge gaps, for example, limited understanding of the underlying pathophysiology and the reason for the heterogenous geographical distribution of reported complications. An adapted case definition of severe vivax malaria would facilitate surveillance and future research to better understand this condition.

Author summary

Why was this study done?
• Historically, the clinical impact of the relapsing malaria caused by Plasmodium vivax has been understudied and reported compared to falciparum malaria.

What did the researchers do and find?
• We reviewed the literature on the clinical impact of vivax malaria focusing on children and pregnant women and performed a rapid systematic review of published evidence for severe disease and meta-analysis of selected studies.

• Vivax malaria in young children is associated with severe anemia and increased mortality. Infections in pregnancy lead to maternal anemia, prematurity, fetal loss, and low birth weight. We estimated the proportion of patients with World Health Organization (WHO)-defined severe disease as 0.7% [95% confidence interval (CI) 0.19% to 2.57%] in all patients with vivax malaria and the mortality from vivax malaria as 0.01% [95% CI 0.00% to 0.07%] in all patients and 0.56% [95% CI 0.35% to 0.92%] in hospital settings.

What do these findings mean?
• Reporting of severe vivax malaria has increased dramatically over the last 10 years, but different case definitions have been applied.

• Limitations of our analysis include high risk of bias of published studies, the majority of which are in hospitalized patients (who are therefore more likely to be severely unwell), while most vivax malaria is managed in primary care. As a result, estimates should be interpreted with caution.

• Prospective cohort studies using an adapted case definition of severe vivax malaria would improve estimates of incidence.

• Preventing vivax malaria and subsequent relapses in children and pregnant women is a priority to reduce morbidity and mortality.
Introduction

Like Plasmodium falciparum, the Plasmodium vivax parasite has an intraerythrocytic life cycle lasting approximately 48 hours from red cell invasion by merozoites to schizont rupture. In synchronous infections, schizogony triggers a febrile paroxysm every 3 days, hence the term “tertian fever” given to early descriptions of patients with vivax or falciparum malaria. Malaria caused by P. vivax was termed benign tertian malaria because the clinical course was generally considered to be mild compared to falciparum malaria even though occasional descriptions of severe, including cerebral, presentations of vivax malaria have been reported since 1902 [1]. The notion that P. vivax only rarely causes severe malaria has been challenged over the last 15 years [2], and reports of severe disease have been increasing. More evidence for the negative impacts of vivax malaria on young children and pregnant women has emerged over the same time period. Here, we describe the clinical symptoms and major clinical impacts of malaria caused by P. vivax taking a narrative approach but incorporating a rapid systematic review of the evidence for severe disease.

Rapid review methods

We searched PubMed for articles in English (including those with an English abstract only) documenting severe vivax malaria published until August 1, 2021, using a variety of terms to search title and abstract (S1 Table). Articles were screened by one reviewer (APP) with 20% screened by a second reviewer (PD or EAA). Extra references were identified from other systematic reviews, bibliographic searches, and searching in Google Scholar. This review is reported as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline (S2 Table).

Definitions

We included articles if the authors classified the episode as severe vivax malaria. We noted whether the cases met the case definition of severe (falciparum) malaria published by the World Health Organization (WHO) in 2014 [3], without taking parasite density into account in the definitions of jaundice or anemia (Table 1).

Statistical analysis

The proportion of patients with severe vivax malaria was estimated using a meta-analysis of single proportions using data from studies with clearly defined denominators (case reports, case series, and studies exclusively in pregnant women were excluded), after applying logit transformation. Heterogeneity was assessed using the $I^2$ statistic, which quantifies the proportion of total variability attributable to between-study differences [4]. Pooled estimates derived from the fixed-effect and random-effects meta-analyses were expressed as percentages and presented together with the associated 95% confidence intervals (CIs). The estimates were stratified by geographical region and by hospitalization status (when the information was available) defined as hospitalized only or studies in which the denominator was patients diagnosed in community/outpatient settings as well as inpatients. Similar meta-analyses were carried out for estimating the proportion of patients with the 3 leading complications of cerebral malaria, acute kidney injury (AKI), and pulmonary edema急性 respiratory distress syndrome (ARDS). Severe anemia was not included in the meta-analysis because our search strategy was not designed to capture the literature on vivax malaria and anemia comprehensively. Small study effect was assessed by using a linear regression test of funnel plot asymmetry and bias-adjusted estimates were reported using trim-and-fill method.
Risk of bias assessment

The following aspects of the studies regarding patient selection and outcome assessment domains were considered: representativeness of the cohort (or cases in case–control studies), methodology used for ascertainment of exposure (microscopy, rapid diagnostic tests, and PCR), and if the assessment of exposure and outcome was blinded or not (laboratory procedures blinded or not).

Case series and case reports were not included in the risk of bias assessment.

Clinical features of vivax malaria

Studies of experimentally induced malaria and studies of returned United States servicemen provided early detailed descriptions of clinical features of vivax malaria in nonendemic areas. In a case series of 195 nonimmune adult prison volunteers given sporozoite-induced infections of the Chesson strain of *P. vivax* by US researchers in the 1940s, the most common symptoms reported, apart from fever, were headache, anorexia, nausea, myalgia, abdominal pain, eye pain, chest pain, cough, asthenia, and dizziness [5,6]. Vomiting, splenomegaly, epistaxis, urticaria, diarrhea, edema (not specified), jaundice, and hepatomegaly were typical clinical observations. A mean drop of hemoglobin (Hb) of 2.9 grams/dl was reported over the first 7 days of illness. Five participants who were observed over 15 days of illness experienced a mean Hb drop of 6.4 g/dL. By comparison, a systematic review of 1,975 patients of all ages in endemic areas with vivax malaria treated with chloroquine reported a maximum fall in mean Hb from
12.2 g/dL [95% CI 11.9, 12.5] before treatment to 11.6 g/dL [11.4, 11.9] 2 days later, with recovery by day 42 (12.9 g/dL [12.6, 13.2]) [7]. Patients with recurrent parasitemia had a Hb on average 0.7 g dL [0.5 to 0.9] lower on day 42 than patients with no recurrence (p < 0.001) [7]. *P. vivax* DNA has been detected by PCR from patients meeting the criteria for hyperreactive malarial splenomegaly; however, since *P. vivax* frequently cocirculates with *P. falciparum*, it has not been established definitively that *P. vivax* alone may be the cause [8].

In endemic regions, young children and pregnant women are particularly vulnerable to the negative clinical impacts of infection with *P. vivax*. There is no strong evidence for an interaction between vivax malaria and HIV, although few studies have looked at coinfection [9].

**Clinical impact of vivax malaria in young children**

Symptoms of vivax malaria in children are nonspecific. Fever is typical but not universal and is often accompanied by rigors, vomiting, loose stools, poor feeding and irritability in infants, and sometimes, convulsions. Hepatosplenomegaly is common with an enlarged spleen described more frequently than an enlarged liver [10–14]. In areas where the population acquire immunity following repeated vivax infections, asymptomatic parasitemia is well recognized, and a high proportion of this is submicroscopic [13,15–17]. In a longitudinal study from a low-transmission area along the Thai–Myanmar border from 1991 to 1992, vivax malaria was most common in young children, and 43% of infections in children aged 4 to 15 years were asymptomatic, compared to only 16% of falciparum infections. Incidence of *P. vivax* declined with increasing age, while *P. falciparum* incidence peaked between 20 and 29 years [13]. A cohort study in 2006 of 264 children aged 1 to 3 years in a higher transmission setting in Papua New Guinea found that incidence of *P. vivax* decreased with age, while incidence of *P. falciparum* increased until 30 months of age and then remained stable. There was marked seasonal variation in *P. falciparum* infections, but not *P. vivax* infections, attributed to the propensity of *P. vivax* to relapse [18]. Relapse is common, and the periodicity depends on the infecting strain, the entomological inoculation rate, the number of sporozoites inoculated, the degree of immunity, and the treatment administered [19,20].

In Papua, Indonesia, young children experience a high number of recurrent episodes of vivax malaria early in life, and *P. vivax* in this area is highly chloroquine resistant. Observational data of 7,499 children below 5 years of age who presented to a large hospital between 2004 and 2013 and were diagnosed with vivax malaria showed that they were at greater risk of recurrent malaria than children with falciparum malaria [21]. Among 1,375 children with *P. vivax* infection admitted to hospital for parenteral antimalarial treatment, 28 (3.4%) died within 30 days. In the same analysis, the risk of dying within 30 days among children with *P. vivax* infection who were undernourished (weight for age or height/length for weight z scores below −3 SD of standard reference) was 15.5% (15/97). Children were followed up for 1 year, and the risk of dying between 31 and 365 days after their initial presentation in children diagnosed with vivax malaria was 1.0% (95% CI 0.8 to 1.3). The risk increased to 3.9% (3/77) in undernourished children. In another study from Venezuela, 26% of 78 children requiring hospitalization for vivax malaria were malnourished [22]. The relationship between malaria and nutritional status is complex and not well understood, with different studies suggesting that malnutrition may result from malaria, may increase susceptibility to malaria, or may be protective against malaria [21,23,24]. A serious consequence of repeated episodes of vivax malaria in children is severe anemia [25,26]. Another study from Papua, Indonesia found that infants aged 3 months or younger with vivax malaria were at higher risk of severe malarial anemia (Hb <5g/dL) than infants from the same population with falciparum malaria (odds ratio 2.4; 95% CI 1.0 to 5.9; p = 0.041) [12].
Malaria caused by *P. vivax* has been associated with cognitive impairment and poor school performance. In a study of children aged 6 to 14 years in Sri Lanka, who were monitored for 6 years, repeated episodes (≥3) of vivax malaria were associated with impaired performance in language and mathematics compared to children experiencing fewer than 3 episodes [27]. The same research team went on to conduct a double-blind, placebo-controlled trial of chloroquine prophylaxis in 587 children using attendance rates and language and mathematics scores to evaluate the intervention [28]. The children who received chloroquine experienced fewer episodes of malaria (35% reduction in incidence), were less likely to be absent from school, and scored higher in language and mathematics.

**Clinical impact of vivax malaria in pregnancy**

Vivax malaria in pregnancy is associated with fetal loss, maternal anemia, low birth weight, and preterm birth with occasional reports of congenital infection [29,30]. Asymptomatic infection also occurs in pregnant women [31]. Much of the evidence for the impact of vivax malaria in pregnancy comes from large observational cohort studies of women receiving antenatal care in Asia and has accrued gradually [32,33]. A retrospective analysis of records of 17,613 pregnant women in the first trimester who received antenatal care in clinics along the Thailand–Myanmar border, where *falciparum* and vivax malaria were coendemic, between 1986 and 2010, found that the odds of miscarriage increased in women with asymptomatic (adjusted odds ratio 2.70, 95% CI 2.04 to 3.59) or symptomatic (3.99, 3.10 to 5.13) malaria with similar results for both *P. falciparum* and *P. vivax* [34].

A systematic review and meta-analysis examining the risk of stillbirth related to malaria in pregnancy, which included 59 studies, found that vivax malaria at the time of delivery, but not earlier during the pregnancy, increased the odds of stillbirth (2.8 [95% CI 0.8 to 10.2]) [35]. The relationship between vivax malaria and stillbirth was explored further in a retrospective analysis of a cohort of 61,836 women attending antenatal clinics along the Thailand–Myanmar border between 1986 and 2015, of whom 9,350 (15%) had malaria in pregnancy, and 526 (0.8%) had stillbirths [30]. The hazard of antepartum (and not intrapartum) stillbirth increased 2.2-fold (95% CI 1.1, 4.3; *p* = 0.021) among women who had symptomatic vivax malaria in the third trimester.

Data from the same cohort were used to assess the risk of preterm birth and small for gestational age (SGA) infants [36]. Having vivax malaria from 24 to 28 weeks’ gestation was associated with very preterm (≥28 and <32 weeks) birth (odds ratio 1.8 [95% CI 1.1, 2.9]), while between 28 and 32 weeks, it was associated with late preterm (≥32 and <37 weeks) birth (OR: 1.23 [1.0, 1.5]). Vivax malaria after 20 weeks’ gestation was associated with SGA infants (OR range: 1.12 to 1.54; *p*-value range: <0.001 to 0.138).

Between 2004 and 2006, a cross sectional study in Papua, Indonesia examined the relationship between malaria at delivery and pregnancy outcomes in 2601 women [37]. A decrease in birth weight associated with maternal *P. vivax* infection of 108 g (95% CI 17.5 to 199) was reported. *P. vivax* infection was also associated with an increased risk of moderate, but not severe, maternal anemia compared to no malaria with a reduction of Hb concentration of 0.4 g/dl (95% CI 0.1 to 0.7 g/dL).

A prospective observational study of 1,180 Brazilian pregnant women over 1 year from 2015 to 2016, 8% of whom had malaria (75% caused by *P. vivax*), showed that malaria episodes were associated with decreased birth weight and length and maternal anemia [38]. Birth weight z-scores showed a mean reduction of 0.35 (95% CI 0.14 to 0.57) in women with malaria in the second or third trimester compared to those with no malaria. The corresponding mean reduction in birth length z-scores was 0.31 (95% CI 0.08 to 0.54). Women with malaria in the second
or third trimester also had a Hb concentration on average 0.33 g/100 mL lower (95% CI 0.05 to 0.62 g/100 mL). Of 637 cord blood samples tested by PCR, *P. vivax* was found in 4 cases.

Increased infant mortality has been associated with maternal vivax malaria during pregnancy. In a prospective study from a low-transmission setting along the Thailand–Myanmar border of a cohort of 1,495 mothers followed weekly throughout pregnancy and then with their infants until 1 year of life, malaria during pregnancy (any species) increased neonatal mortality by causing low birth weight, and fever in the week before delivery was also associated with increased infant mortality [39].

To date, interventional chemoprevention studies in pregnancy have not demonstrated a reduction in *P. vivax* malaria–related adverse pregnancy outcomes. In a randomized, double-blind, placebo-controlled trial of weekly chloroquine prophylaxis in 1,000 pregnant women on the Thai–Myanmar border, no women who received chloroquine had an episode of vivax malaria compared to 10% women in the placebo arm who experienced at least one [40]. Despite preventing episodes of vivax malaria, the proportions of women with anemia (hematocrit <30%) during the study in chloroquine and placebo arms were similar in both groups at 71.2% (336/472) and 71.4% (342/479), respectively (*p* = 0.76). No difference was observed between the groups in mean birth weight, proportion of low birth weight infants, or preterm delivery.

**Placental changes with vivax malaria.** Histopathological studies of placenta from women with vivax malaria during pregnancy have generally shown less evidence of intervillous inflammation or placental involvement in comparison to falciparum malaria [41–44]. In an ex vivo study reported from Thailand, *P. vivax* isolates were shown to adhere to chondroitin sulfate, the main receptor for adhesion of *P. falciparum* parasitized erythrocytes in the placenta [45].

**Severe vivax malaria**

**Results of rapid systematic review.** The search for all severe manifestations of vivax malaria yielded 2,053 results. After screening title, abstract, and full text and removing duplicates, 1,696 articles were excluded (S1 Fig), leaving 423 for quantitative synthesis. There were 208 case reports or case series, 100 articles reporting prospective studies, and 115 retrospective studies. Fewer than 7 articles were published per year until 2002. Then the numbers gradually increased, peaking at 60 in 2013 (Fig 1). A total of 11 articles did not present the number of patients, only the number of severe complications; therefore, we cannot give the precise number of patients in our review. A total of at least 11,658 patients with at least 1 manifestation of severe vivax malaria were reported from 423 articles (Fig 2, S3 Table) across 45 countries, with over 60% of cases reported from 2 countries: India (43.9%, *n* = 5,114) and Indonesia (23.5%, *n* = 2,743). To confirm the diagnosis of *P. vivax* monoinfection, microscopy only was used in 35% (148) articles, molecular methods were used to confirm microscopy findings in 20% (85) articles, rapid diagnostic tests were used alone or in combination to confirm microscopy in 33% (139), PCR only was used in 4 cases, and diagnostic methods were not available in 8% (35) articles. There were only 5 cases with a parasite density reported in excess of 100,000/μL.

Laboratory diagnostics to exclude other comorbidities or concurrent illness, e.g., blood culture and dengue rapid diagnostic test, were performed to varying degrees of comprehensiveness in 224 (53%) articles and not done or not mentioned in 189 (44%).

**Results of meta-analysis.** A total of 92 studies were eligible for inclusion in the meta-analysis using both random effects and fixed effect models (S4 Table). Heterogeneity, assessed using the $I^2$ statistic, was very high. From our risk of bias assessment focusing on
3 domains, representativeness of the population was at high or unclear risk of bias for 42% of studies, half of the studies were retrospective and judged to be at high risk of bias and for ascertainment of exposure, which took diagnostic methods into account, while 72% were at moderate or unclear risk of bias (S5 Table). Most of the studies in the meta-analysis were from Asia \( (n = 67) \), and the majority (69) were conducted in hospital settings. In terms of patient numbers, of 4,547 patients with severe malaria included, approximately one-third were from Latin America. Only 85 studies could be assessed in the meta-analysis to estimate the proportion of severe vivax malaria because not all studies reported the number of patients with severe malaria, only the number of complications (Table 2). The random-effects estimate of the proportion of patients with WHO-defined severe disease was 0.7% [95% CI 0.19% to 2.57%] in studies that included all patients diagnosed with vivax malaria (inpatient and outpatient) and 7.11% [95% CI 4.30% to 11.55%] in studies of hospitalized patients (Table 2). Estimates using author definitions of severe malaria which included severe thrombocytopenia without bleeding were approximately 2-fold higher. Estimates adjusted for small study effects for all proportions are shown in the Supporting information (S6 Table). There were 4 studies exclusively in pregnant women (S7 Table). In a random-effects meta-analysis of these studies including 225 women, we estimated the proportion with severe malaria as 4.14% [95% CI 0.82% to 18.43%]. Further estimates of proportion with severe malaria stratified by hospitalization status within each region are presented as a Supporting information table (S8 Table).
Cerebral malaria

We found 163 articles describing 1,502 patients with cerebral manifestations of vivax malaria. Among the cerebral complications in these patients, 645 (42.9%) fulfilled WHO criteria for cerebral malaria (S3 Table), 278 (18.5%) had seizures only with no other features of cerebral malaria, and 579 (38.6%) had cerebral symptoms such as altered consciousness or sensorium, confusion, and/or low but unquantified Glasgow Coma Scores. Over 75% of cerebral malaria cases were reported from one of India (53.7% (807/1,502)), Colombia (11.9% (178/1,502)), or Indonesia (10.2% (153/1,502)) (Fig 2). A small number of articles described retinal changes, including hemorrhages, cotton wool spots, and papilledema occurring in complicated vivax malaria [46]. Vivax malaria has also been reported as presenting as a cerebral infarct or cerebral venous sinus thrombosis [47,48].

From these reports, 90 articles were eligible for inclusion in the meta-analysis of cerebral vivax malaria. The random-effects estimate of the proportion of the patients from all studies with WHO-defined cerebral malaria was 0.62% [95% CI 0.33% to 1.18%] among hospitalized patients and 0.02% [95% CI 0.00% to 0.13%] among patients from studies that included all patients diagnosed with vivax malaria (inpatient and outpatient) (Table 3).

https://doi.org/10.1371/journal.pmed.1003890.g002
Postmalaria neurological syndrome (PMNS)

We found 8 (0.07%) reports of PMNS: 4 cases of acute disseminated encephalomyelitis (ADEM), 2 of Guillain–Barré syndrome, 1 report of a patient with behavior change, and 1 of myelitis.

Respiratory manifestations of severe vivax malaria

Of 1,202 patients with respiratory complications reported from 97 articles, 258 (21.5%) fulfilled WHO criteria for pulmonary edema (chest radiograph confirmed or $O_2$ saturations <92% with respiratory rate more than 30/min); 330 (26.6%) were reported to have ARDS; and 593 (48.6%) had other respiratory complications such as respiratory distress (not otherwise specified), pleural effusion, and pneumothorax (Fig 2).

From the meta-analysis of respiratory complications in 87 studies (Table 3), the proportion of patients with WHO-defined pulmonary edema was 0.66% [95% CI 0.38% to 1.13%] in

---

Table 2. Estimating the proportion of vivax malaria that were classified as severe in studies eligible for inclusion in the meta-analysis.

| Definition of severe malaria | Number of articles | $n/N$ | Fixed effect [95% CI] | $I^2$ | Random effects [95% CI] |
|-----------------------------|-------------------|-------|-----------------------|-------|------------------------|
| **WHO definition**          |                   |       |                       |       |                        |
| Overall                     | 84                | 4,518/818,808 | 0.55% [0.54% to 0.57%] | 99.6% | 4.37% [2.60% to 7.25%] |
| **Stratified by region**    |                   |       |                       |       |                        |
| Africa                      | 5                 | 73/3,306 | 2.21% [1.76% to 2.77%] | 93.7% | 1.62% [0.18% to 12.94%]|
| Asia                        | 66                | 3,572/330,131 | 1.08% [1.05% to 1.12%] | 99.5% | 7.29% [4.47% to 11.67%]|
| Oceania                     | 1                 | 16/1,946 | 0.82% [0.50% to 1.34%] | –     | 0.82% [0.50% to 1.34%] |
| South America               | 13                | 857/483,425 | 0.18% [0.17% to 0.19%] | 99.2% | 0.58% [0.12% to 2.87%] |
| **Stratified by settings**  |                   |       |                       |       |                        |
| Hospitalized                | 66                | 2,594/35,822 | 7.24% [6.98% to 7.51%] | 97.1% | 7.11% [4.30% to 11.55%]|
| All (including outpatients)$^b$ | 14             | 1,836/780,960 | 0.24% [0.22% to 0.25%] | 99.5% | 0.70% [0.19% to 2.57%] |
| Other$^c$                   | 4                 | 88/2,026 | 4.34% [3.54% to 5.32%] | 93.9% | 1.92% [0.26% to 12.66%]|
| **All definitions**         |                   |       |                       |       |                        |
| Overall                     | 82                | 6,063/818,541 | 0.74% [0.72% to 0.76%] | 99.7% | 11.53% [8.09% to 16.18%]|
| **Stratified by region$^d$** |                   |       |                       |       |                        |
| Africa                      | 5                 | 202/3,306 | 6.11% [5.34% to 6.98%] | 97.9% | 9.69% [3.54% to 23.84%]|
| Asia                        | 64                | 4,226/329,864 | 1.28% [1.24% to 1.32%] | 99.6% | 16.02% [11.46% to 21.94%]|
| Oceania                     | 1                 | 100/1,946 | 5.14% [4.24% to 6.21%] | –     | 5.14% [4.24% to 6.21%] |
| South America               | 13                | 1,535/483,425 | 0.32% [0.30% to 0.33%] | 99.5% | 2.24% [0.72% to 6.78%] |
| **Stratified by settings$^d$** |                   |       |                       |       |                        |
| Hospitalized                | 65                | 3,420/3,574 | 9.57% [9.27% to 9.80%] | 97.5% | 17.74% [13.19% to 23.42%]|
| All (including outpatients)$^b$ | 14             | 2,560/780,960 | 0.33% [0.32% to 0.34%] | 99.9% | 1.57% [0.61% to 4.00%] |
| Other$^c$                   | 3                 | 83/1,839 | 4.51% [3.65% to 5.56%] | 96.8% | 5.06% [1.18% to 19.22%] |

$n = \text{Number of patients with severe vivax malaria}; N = \text{total number of patients with vivax malaria}.$

$^a$Studies that were carried out exclusively among pregnant women are excluded; studies that include few or some pregnant women were not excluded.

$^b$Studies that predominantly reported data on outpatients settings were also included.

$^c$Other includes studies that did not mention the settings and the studies in which the number of patients who were hospitalized or treated outpatients could not be reliably extracted.

$^d$Estimates stratified by settings within each region is presented in additional file (S8 Table).

When region and settings were adjusted using a multivariable logistic regression model with study as the random effects, the difference between the settings (hospitalization versus not) remained, whereas the difference between regions (Africa versus Asia and South America versus Africa) was not significant. Interaction between region and settings was not significant ($p = 0.278$ for the test of interaction using all definitions of severe vivax and $p = 0.081$ for WHO definition).

CI, confidence interval; WHO, World Health Organization.

https://doi.org/10.1371/journal.pmed.1003890.t002
studies among patients who were hospitalized and 0.00% [95% CI 0.00% to 0.07%] in studies that included all patients diagnosed with vivax malaria (inpatient and outpatient). Only a few articles (32/138) enumerated the time of onset of pulmonary symptoms relative to starting

---

### Table 3. Estimating proportion of patients with cerebral malaria, renal complications, and respiratory complications in studies eligible for inclusion in the meta-analysis.

|                          | Number of articles<sup>a</sup> | n/N                  | Fixed effect [95% CI] | I² | Random effects [95% CI] |
|--------------------------|-------------------------------|----------------------|-----------------------|----|------------------------|
| **Cerebral malaria**     |                               |                      |                       |    |                        |
| WHO definition           |                               |                      |                       |    |                        |
| Overall                  | 90                            | 636/820,671          | 0.08% [0.07% to 0.08%] | 97.7% | 0.28% [0.14% to 0.56%] |
| Hospitalized             | 71                            | 466/37,602           | 1.24% [1.13% to 1.36%] | 89.8% | 0.62% [0.33% to 1.18%] |
| All (including outpatients)<sup>b</sup> | 14                            | 156/780,960          | 0.02% [0.02% to 0.02%] | 98.3% | 0.02% [0.00% to 0.13%] |
| Other<sup>c</sup>         | 5                             | 14/2,109             | 0.66% [0.39% to 1.12%] | 80.9% | 0.10% [0.00% to 3.68%] |
| All definitions          |                               |                      |                       |    |                        |
| Overall                  | 90                            | 962/820,671          | 0.12% [0.11% to 0.12%] | 98.3% | 0.83% [0.51% to 1.35%] |
| Hospitalized             | 71                            | 631/37,602           | 1.68% [1.55% to 1.81%] | 91.2% | 1.43% [0.90% to 2.25%] |
| All (including outpatients)<sup>b</sup> | 14                            | 310/780,960          | 0.04% [0.04% to 0.04%] | 98.5% | 0.10% [0.03% to 0.32%] |
| Other<sup>c</sup>         | 5                             | 21/2,109             | 1.00% [0.65% to 1.52%] | 84.1% | 0.87% [0.13% to 5.69%] |
| **Renal**                |                               |                      |                       |    |                        |
| WHO definition           |                               |                      |                       |    |                        |
| Overall                  | 89                            | 447/820,351          | 0.05% [0.05% to 0.06%] | 89.7% | 0.18% [0.08% to 0.39%] |
| Hospitalized             | 70                            | 405/37,282           | 1.09% [0.99% to 1.2%]  | 87.7% | 0.26% [0.12% to 0.68%] |
| All (including outpatients)<sup>b</sup> | 14                            | 39/780,960           | 0.00% [0.00% to 0.01%] | 91.2% | 0.01% [0.00% to 0.10%] |
| Other<sup>c</sup>         | 5                             | 3/2,109              | 0.14% [0.05% to 0.44%] | 0.0%  | 0.14% [0.05% to 0.44%] |
| All definitions          |                               |                      |                       |    |                        |
| Overall                  | 88                            | 810/820,248          | 0.1% [0.09% to 0.11%]  | 95.0% | 0.49% [0.25% to 0.97%] |
| Hospitalized             | 69                            | 759/37,179           | 2.04% [1.9% to 2.19%]  | 94.1% | 1.29% [0.73% to 2.26%] |
| All (including outpatients)<sup>b</sup> | 14                            | 48/780,960           | 0.01% [0.00% to 0.01%] | 93.0% | 0.02% [0.00% to 0.19%] |
| Other<sup>c</sup>         | 5                             | 3/2,109              | 0.14% [0.05% to 0.44%] | 0.0%  | 0.14% [0.05% to 0.44%] |
| **Respiratory**          |                               |                      |                       |    |                        |
| WHO definition           |                               |                      |                       |    |                        |
| Overall                  | 87                            | 414/819,669          | 0.05% [0.05% to 0.06%] | 92.6% | 0.23% [0.11% to 0.47%] |
| Hospitalized             | 69                            | 352/37,233           | 0.95% [0.85% to 1.05%] | 86.6% | 0.66% [0.38% to 1.13%] |
| All (including outpatients)<sup>b</sup> | 13                            | 57/780,327           | 0.01% [0.01% to 0.01%] | 85.5% | 0.00% [0.00% to 0.07%] |
| Other<sup>c</sup>         | 5                             | 5/2,109              | 0.24% [0.1% to 0.57%]  | 55.0% | 0.27% [0.06% to 1.16%] |
| All definitions          |                               |                      |                       |    |                        |
| Overall                  | 87                            | 848/819,669          | 0.10% [0.10% to 0.11%] | 98.1% | 0.66% [0.41% to 1.05%] |
| Hospitalized             | 69                            | 450/37,233           | 1.21% [1.10% to 1.32%] | 90.4% | 1.00% [0.62% to 1.61%] |
| All (including outpatients)<sup>b</sup> | 13                            | 393/780,327          | 0.05% [0.05% to 0.06%] | 98.8% | 0.18% [0.06% to 0.53%] |
| Other<sup>c</sup>         | 5                             | 5/2,109              | 0.24% [0.10% to 0.57%] | 55.0% | 0.27% [0.06% to 1.16%] |

<sup>a</sup>Studies that were carried out exclusively among pregnant women are excluded; studies that include few or some pregnant women were not excluded.

<sup>b</sup>Studies that predominantly reported data on outpatient settings were also included.

<sup>c</sup>Other includes studies that did not mention the settings and the studies in which the number of patients who were hospitalized or treated outpatients could not be reliably extracted.

CI, confidence interval; WHO, World Health Organization.

https://doi.org/10.1371/journal.pmed.1003890.t003
malaria treatment; symptoms developed before malaria therapy in 96 patients, after in 84 patients, and for the remainder the time of onset were not specified.

Lung histology. Histological findings from one fatal case report from India included alveolar damage and hyaline membrane formation, typical of ARDS [49]. A Brazilian postmortem series of 13 patients found ARDS and pulmonary edema in 2 and 5 cases, respectively. The pathologist reported scattered parasitized red blood cells in capillaries in the lungs of one of the patients with ARDS.

Renal manifestations of severe vivax malaria

Among 1,694 patients with biochemical evidence of impaired renal function, 915 (54.0%) met WHO criteria for AKI (S3 Table), 233 (13.8%) cases were classified using the Kidney Disease: Improving Global Outcomes (KDIGO) [50] or Risk, Injury, Failure, Loss, End-Stage Renal Disease (RIFLE) [51] classifications, and 546 (32.2%) were categorized using local definitions with different urea or creatinine cutoffs. More than 75% (1,694/1,272) of renal complications were reported from India (Fig 2). From the random-effects meta-analysis of renal complications from 89 eligible articles, we estimated that 0.51% [95% CI 0.26% to 0.98%] patients met WHO criteria for AKI in studies of hospitalized patients and 0.01% [95% CI 0.00% to 0.10%] in studies that included all patients diagnosed with vivax malaria (inpatient and outpatient) (Table 3).

Renal histology. We found reports of renal biopsy results from 45 patients with renal impairment and vivax malaria (S9 Table). The most common histological diagnosis was acute tubular necrosis (n = 20), with a second diagnosis reported in 9 cases; cortical necrosis was reported in 16, thrombotic microangiopathy in 12, and mesangiocapillary glomerulonephritis in 7 patients.

Mortality from vivax malaria

A total of 553 deaths were associated with severe vivax malaria (S3 Table). Out of these, 334 were from 75 studies eligible for inclusion in the random-effects meta-analysis, and the overall

| Stratified by region | Number of articles | n/N                  | Fixed effect [95% CI] | I² | Random effects [95% CI] |
|---------------------|-------------------|----------------------|-----------------------|----|------------------------|
| Overall             | 75                | 334/814,505          | 0.04% [0.04% to 0.05%] | 96.2 | 0.27% [0.15% to 0.5%]   |
| Stratified by region|                   |                      |                       |     |                        |
| Africa              | 2                 | 0/2,263              | 0.00% [0.00% to 0.17%]d | to  | 0.00% [0.00% to 0.17%]d |
| Asia                | 62                | 271/329,257          | 0.08% [0.07% to 0.09%] | 93.8 | 0.50% [0.29% to 0.84%]  |
| Oceania             | –                 | –                    | –                     | –   | –                      |
| South America       | 12                | 63/482,985           | 0.01% [0.01% to 0.02%] | 95.8 | 0.03% [0.00% to 0.24%]  |
| Stratified by settings|                |                      |                       |     |                        |
| Hospitalized        | 61                | 234/36,087           | 0.65% [0.57% to 0.74%] | 80.6 | 0.56% [0.35% to 0.92%]  |
| All (including outpatients)b | 11       | 82/778,041           | 0.01% [0.01% to 0.01%] | 95.2 | 0.01% [0.00% to 0.07%]  |
| Otherc             | 3                 | 18/377               | 4.77% [3.03% to 7.45%] | 75.6 | 2.50% [0.59% to 9.98%] |

n = Number of patients who died; N = total number of patients with vivax malaria.

aStudies that were carried out exclusively among pregnant women are excluded; studies that include few or some pregnant women were not excluded.
bStudies that predominantly reported data on outpatients settings were also included.
cOther includes studies that did not mention the settings and the studies in which the number of patients who were hospitalized or treated outpatients could not be reliably extracted.
d95% CIs were obtained using Wilson’s method ignoring the site effects. CI, confidence interval.

https://doi.org/10.1371/journal.pmed.1003890.t004
estimate of mortality (all studies, regardless of setting) was 0.27% [0.15% to 0.50%] (Table 4). There were no reports of deaths from the African region.

**Postmortem evidence of severe malaria**

In a retrospective review of the postmortem findings of 17 patients who had died with vivax malaria between 1996 and 2010 in a single centre in Brazil, it was concluded that vivax malaria was the probable cause of death or contributed to the fatal outcome in 13 cases aged between 8 and 88 years [52]. Pulmonary edema or ARDS were the leading causes of death (n = 7), coexisting with splenic rupture in 2 patients. The other causes of death were multiple organ dysfunction (n = 3, including one with a cerebrovascular accident), primaquine-induced hemolytic anemia in the context of glucose-6-phosphate dehydrogenase (G6PD) deficiency (n = 2), and isolated splenic rupture (n = 1). A total of 7 patients had comorbidities such as hepatic cirrhosis or pulmonary emphysema. Postmortem findings consistent with ARDS were reported from one fatal case in India [49].

Postmortem histology from one fatal case of “infection with (the) large tertian parasite” in 1902 [1] found a spleen containing numerous large parasites, tubular degeneration in the kidneys, pigment in lung capillaries but no parasites, and very little evidence of pigment or parasitized erythrocytes in the brain. Another postmortem study of a Vietnamese patient with severe vivax malaria who died suddenly but was fully conscious on presentation found no evidence of sequestration of parasitized erythrocytes in the cerebral microvasculature [53].

**Pathophysiology of severe vivax malaria**

Theories as to the pathophysiological processes underlying severe disease include immune dysfunction [54–59], parasite strain–specific virulence [60–62], inflammation triggered by cytokines, and endothelial cell dysfunction [63]. A proteomic study testing serum from Indian patients with vivax malaria of differing levels of severity as well as controls has given signals of possible involvement of oxidative stress pathways, cytoskeletal regulation, lipid metabolism, and complement cascades [64]. Waning immunity as transmission goes down and increasing resistance of *P. vivax* to chloroquine have been put forward as possible explanations for increasing reports of severe vivax malaria [54,65]. Increased expression of *pvcrt-o* (*P. vivax* chloroquine resistance transporter-o), *pvmdr-1* (*P. vivax* multidrug resistance gene-1), and *vir* (variant interspersed repeats) genes has been shown in small numbers of patients with severe compared to uncomplicated vivax malaria [66–68].

Studies of patients with malaria have shown *P. vivax* evokes relatively higher concentrations of pro- and anti-inflammatory cytokines, such as tumor necrosis factor (TNF), and other markers of host immune response than *P. falciparum* at similar parasite densities [69,70]. While these findings can explain the lower pyrogenic parasite densities of vivax infections compared to falciparum, TNF is not thought to play a causal role in coma and cerebral manifestations of severe falciparum malaria [71]. Some in vitro studies have demonstrated some cytoadhesive properties of *P. vivax* parasitized erythrocytes [72]; however, cytoadherence and/or sequestration have not been demonstrated in vivo, and there are no published postmortem studies of patients diagnosed with cerebral vivax malaria. Binding of uninfected erythrocytes to parasitized erythrocytes (rosetting) does occur, which may lead to impaired circulation [73,74]. Modest (2-fold) increases in peripheral parasite densities in severe disease are accompanied by larger (7-fold) increases in circulating parasite lactate dehydrogenase, suggesting the possibility of parasitized erythrocytes accumulating elsewhere [75].
Impairment of endothelial function has been shown in Malaysian patients with vivax malaria [63]. Endothelial injury and excessive inflammation could also explain ARDS presentations. In a study of pulmonary gas transfer in Indonesian adults with falciparum or vivax malaria diffusing capacity for carbon monoxide (DLCO) in patients with vivax malaria was 93% (95% CI 87 to 104) of predicted values at baseline and declined for 2 weeks after treatment to 84% (95% CI 72 to 95) [76]. Evidence for cytoadherence in the pulmonary microvasculature is not that compelling, although scattered parasitized red blood cells in pulmonary capillaries have been described in one patient postmortem, and P. vivax has been shown to adhere to human lung microvascular endothelial cells (HMVEC-L) in vivo, albeit to a lesser degree than P. falciparum [52,77].

Increased concentrations of platelet-associated IgG (PAIgG) have been reported in patients with thrombocytopenia and vivax malaria, of unclear significance [78]. It has also been postulated that increased levels of macrophage colony–stimulating factor in vivax and falciparum malaria may result in increased macrophage-mediated platelet destruction and thrombocytopenia [79].

The anemia associated with P. vivax malaria has been reviewed in detail by Douglas and colleagues [25]. Mechanisms by which malaria leads to anemia include destruction of parasitized erythrocytes, destruction of nonparasitized erythrocytes, and dyserythropoiesis. Unlike in falciparum malaria, it is unusual to have parasite densities more than 2% infected erythrocytes in acute vivax malaria [80]. P. vivax has a predilection for invading younger erythrocytes, which has been thought to be one reason why unrestricted parasite multiplication does not occur as for P. falciparum. However, severity of anemia may be comparable, or worse. Collins and colleagues postulated that destruction of reticulocytes as they are produced could account for this [81]. However, Kitchen observed in another study published in 1938 that, even when reticulocyte numbers increase, only a fixed proportion will be infected; therefore, other factors may be more important [82]. Survival of uninfected red cells is shortened after an episode of malaria [81]. A mathematical modeling study using parasitemia and Hb data from patients receiving P. falciparum malarial therapy for neurosyphilis estimated that 8.5 nonparasitized erythrocytes were destroyed for each parasitized erythrocyte [83]. In malaria caused by P. vivax, the number may be even higher, given that parasites densities are lower. However, there is only indirect evidence for this. In a study of mean erythrocyte survival after P. falciparum or P. vivax parasitemia in 35 Thai patients who received transfusions of either labeled autologous or donor erythrocytes once their parasitemia had cleared, a similar reduction in erythrocyte survival was seen, regardless of the infecting species and did not appear to be antibody or complement mediated [84]. In a Colombian study comparing patients with uncomplicated and complicated (defined as platelets <50,000/μL, abnormal liver enzymes, or hypoglycemia) vivax malaria, there was an association between autoimmune antibodies and Hb concentrations in complicated disease. There was also a correlation with levels of atypical memory B cells, which have been hypothesized to contribute to anemia in malaria by secreting antibodies against phosphatidylserine on uninfected erythrocytes [85].

In malaria endemic areas, the degree of anemia associated with P. vivax infections depends on transmission intensity, patient age, and by extension degree of acquired immunity, strain relapse periodicity, and choice of antimalarial treatment, e.g., more slowly eliminated drugs will suppress the first relapse, allowing time for hematological recovery, while treatment failure due to resistance will impede recovery.
Discussion

The global burden of vivax infections is vast, with estimates ranging from 7 to 14 million cases annually, leading to a substantial clinical impact, particularly in young children and pregnant women [86,15]. While it is now generally accepted that vivax malaria may manifest as severe disease, uncertainties remain. Reports of severe vivax malaria have increased over the last decade, but it is unclear to what extent this represents a genuine increase in case numbers, increased recognition of the disease, or misattribution in patients with other diagnoses and incidental parasitemia. In Manaus, Brazil, where a consistent case definition has been used over time, the incidence of severe disease has been increasing [87]. Increasing chloroquine resistance might be expected to lead to more severe disease, although in Papua, Indonesia, switching from chloroquine to artemisinin combination therapy did not lead to a mortality reduction in patients hospitalized with vivax malaria, suggesting that relapse prevention may be more important to reduce deaths [88]. This is supported by another analysis of more than 20,000 patients with vivax malaria in the same location showing that P. vivax infection was a risk factor for representation to hospital and contributed to increased mortality [89].

There are major disparities in frequencies of reporting certain complications of vivax malaria from different parts of the world (Fig 2) and a near absence of reporting of severe vivax malaria from some Southeast Asian countries, e.g., Thailand, Myanmar, Vietnam, and Lao PDR. Strain-specific virulence has been described in both induced malaria studies [90] and natural infections such as in the former United Soviet Socialist Republic where outbreaks of “fulminant malaria” caused by P. vivax were well described in the 1940s [91]. While this may be the explanation for the heterogeneous distribution of severe disease, the fact that asymptomatic vivax parasitemia is common means that a degree of misattribution is inevitable. This has been shown in individual fatal cases for whom exhaustive attempts were made to rule out other causes [52,92]. It is also suggested by variable histological findings from patients with vivax malaria who have had a renal biopsy. Only about half of the studies included in this review described attempts to exclude other diagnoses, e.g., sepsis. A 1 year prospective study from Kolkata examined the rate of concomitant bacteremia with P. vivax parasitemia and found that 6/89 (6.7% [95% CI 3.1% to 13.9%]) of patients with P. vivax infection were bacteremic [93].

Our estimate of mortality resulting from P. vivax infection from the random-effects meta-analysis ranged from 0.01% [0.00% to 0.07%] (studies of all patients, i.e., outpatient and inpatient cases) to 0.56% [0.35% to 0.92%] in studies of hospitalized patients only. These results were similar to a case fatality rate estimate of 0.3% (353/46,411) from a fixed-effect meta-analysis in another systematic review, which used a modified WHO definition of severe malaria and included thrombocytopenia [94]. However, these estimates should be interpreted with caution given the risk of bias assessment of included studies.

Detailed studies from a small number of research groups so far have not identified a common pathophysiological process underlying different complications of vivax malaria. Sequestration of parasitized red blood cells in the microcirculation, which is the pathophysiological hallmark of severe falciparum malaria, has been not been demonstrated.

ARDS has been reported with infection from all Plasmodium species causing malaria in humans. Incidence rates of ARDS in severe falciparum malaria have been shown to vary between 2% and 25% and are more likely to lead to a fatal outcome than ARDS with P. vivax [95,96].

The need for an adapted case definition for severe vivax malaria has been recognized for over a decade. Reporting by different groups is inconsistent, impeding gathering reliable incidence data or conducting research. A Brazilian study looking at predictors of intensive care
unit (ICU) admission in patients with vivax malaria found that many of the criteria in the severe falciparum malaria definition were predictive, with the exception of hyperbilirubinemia [87]. The importance of thrombocytopenia as a diagnostic criterion for severe vivax malaria has been debated [97]. Lampah and colleagues from Papua, Indonesia reported the mortality risk of *P. vivax* infections in patients presenting to a referral hospital with severe thrombocytopenia to be 1.5% (25/1650) below $5 \times 10^9$/L and 3.6% (6/168) below $20 \times 10^9$/L in patients with *P. vivax* and proposed the latter threshold as a severity criterion [98]. The utility of this in routine practice would need to be demonstrated since complete blood count is not available in many outpatient settings where malaria is diagnosed and treated [98]. Conversely, incorporating platelet counts into case definitions of severe falciparum malaria using >200,000 per μL to rule out severe malaria has been proposed as a means to improve the specificity of clinical and parasitological diagnosis in a mathematical modeling study. Results suggested that one-third of 2,220 Kenyan children included in studies had been misdiagnosed as having severe malaria [99]. Very few articles reported platelet counts associated with severe syndromes in our review so we were unable to explore this.

Limitations of our rapid systematic review include limiting our search to the English language and omitting to search other databases such as the Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS) database. A systematic review of the Brazilian published and gray literature in 2012 described a similar array of complications from *P. vivax* infection to those reported here [100]. The literature is dominated by case series and reports and by hospital-based studies increasing the risk of bias toward more severely ill patients. Our formal risk of bias assessment of studies included in the meta-analysis indicated a moderate to high risk of bias. There was also evidence of small study effects which was shown in an earlier systematic review by Naing [101].

**Conclusions**

Vivax malaria has emerged from the shadow of falciparum malaria over the last decade with improved recognition of the negative clinical impacts associated with this relapsing infection. Preventing severe anemia associated with relapsing vivax malaria, particularly in very young children, is a priority to reduce morbidity and mortality in this group. Progress has been slowed by low uptake of antihypnozoiticidal treatment with 8-aminoquinoline drugs due to fears of hemolysis in patients with G6PD deficiency, compounded by lack of access to G6PD testing [102].

Prevention of infection with *P. vivax* in pregnancy may need to target young women pre-conception in order to prevent the risk of relapse during pregnancy and the consequent negative impacts of maternal anemia, increased fetal loss, and low birth weight [103]. Severe clinical presentations of vivax malaria are now well recognized, although knowledge gaps persist in terms of understanding the underlying pathophysiology of different complications and the apparent heterogeneity in incidence worldwide. An adapted case definition of severe vivax malaria would facilitate surveillance and future research.

**Supporting information**

S1 Fig. PRISMA flow diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. (PDF)

S1 Table. Search keywords and results. (DOCX)
S2 Table. PRISMA checklist. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
(DOCX)

S3 Table. Summary of severe manifestations of vivax malaria.
(DOCX)

S4 Table. List of studies included in meta-analyses.
(XLSX)

S5 Table. Risk of bias assessment of studies in meta-analyses.
(XLSX)

S6 Table. Assessment of small study effects.
(DOCX)

S7 Table. Summary of studies of severe vivax malaria in pregnant women.
(DOCX)

S8 Table. Proportion of severe vivax stratified by settings within each region.
(DOCX)

S9 Table. Summary of renal biopsy histology from patients with vivax malaria.
(DOCX)

Acknowledgments
The Lao–Oxford–Mahosot Hospital–Wellcome Trust Research Unit (LOMWRU) and the Myanmar Oxford Clinical Research Unit are part of the MORU Tropical Health Network. For the purpose of open access, the author has applied a CC BY public copyright license to any author accepted manuscript version arising from this submission.

References
1. Ewing J. Contribution to the pathological anatomy of malaria fever. J Exp Med. 1902; 6(2):119–80. https://doi.org/10.1084/jem.6.2.119 PMID: 19866969
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007; 77(6 Suppl):79–87. PMID: 18165478
3. World Health Organization. Severe malaria. Trop Med Int Health. 2014; 19(s1):i–vii.
4. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta–analyses. BMJ. 2003; 327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120
5. Whorton CM, Yount E Jr, Jones R Jr, Alving AS, Pullman TN, Craigie B. Jr et al. The Chesson strain of Plasmodium vivax malaria; clinical aspects. J Infect Dis. 1947; 80(3):237–49. https://doi.org/10.1093/infdis/80.3.237 PMID: 20247931
6. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol. 2012; 80:151–201. https://doi.org/10.1016/B978-0-12-397900-1.00003-7 PMID: 23194888
7. Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta–analysis. BMC Med. 2019; 17(1):151. https://doi.org/10.1186/s12916-019-1386-6 PMID: 31366382
8. Mitja O, Hays R, Malken J, Ipai A, Kangapu S, Robson J, et al. HMS–related hemolysis after acute attacks of Plasmodium vivax malaria. Am J Trop Med Hyg. 2011; 85(4):616–8. https://doi.org/10.4269/ajtmh.2011.11-0145 PMID: 21976560
9. Del–Tejo PL, Cubas–Vega N, Caraballo–Guerra C, da Silva BM, da Silva VJ, Sampaio VS, et al. Should we care about Plasmodium vivax and HIV co–infection? A systematic review and a cases series from the Brazilian Amazon. Malar J. 2021; 20(1):13. https://doi.org/10.1186/s12936-020-03518-9 PMID: 33907474
10. Ghosh S, Patwari A, Mohan M, Berry AM. Clinical and hematologic peculiarities of malaria in infancy. A study of 40 infants. Clin Pediatr (Phila). 1978; 17(4):369–71. https://doi.org/10.1177/0009287870170043 PMID: 346290

11. Ahmad SH, Kidwai T, Moonis R, Shahab T, Chandra J. Clinical profile of malaria in children—a prospective study from Aligarh (N. India). Ann Trop Paediatr. 1987; 7(2):82–6. https://doi.org/10.1080/02724936.1987.11748480 PMID: 2441565

12. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis. 2009; 48(12):1704–12. https://doi.org/10.1086/599041 PMID: 19438395

13. Luxemburger C, Thwai KL, White NJ, Webster HK, Kyle DE, Maelankiri L, et al. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg. 1996; 90(2):105–11. https://doi.org/10.1016/s0035-9203(96)90102-9 PMID: 8761562

14. Luxemburger C, Nosten F, Kyle DE, Kiricharoen L, Chongsuphasaiddhi T, White NJ. Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg. 1998; 92(1):45–9. https://doi.org/10.1016/s0035-9203(98)90950-6 PMID: 9692150

15. Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016; 95(6 Suppl):15–34. https://doi.org/10.4269/ajtmh.16-0141 PMID: 27402513

16. Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, et al. The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand–Myanmar border areas, Cambodia, and Vietnam. Malar J. 2015; 14:381. https://doi.org/10.1186/s12936-015-0906-x PMID: 26424000

17. Andrade BB, Reis-Filho A, Souza-Neto SM, Clarencio J, Camargo LM, Barral A, et al. Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J. 2010; 9:13. https://doi.org/10.1186/1475-2875-9-13 PMID: 20070895

18. Lin E, Kinihoro B, Gray L, Dobbie S, Robinson L, Lumaee A, et al. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS ONE. 2010; 5(2):e9047. https://doi.org/10.1371/journal.pone.0009047 PMID: 20140220

19. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011; 10:297. https://doi.org/10.1186/1475-2875-10-297 PMID: 21988376

20. Chu CS, Phtyo AP, Lwin KM, Win HH, San T, Aung AA, et al. Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primarquine in Plasmodium vivax Malaria. Clin Infect Dis. 2018; 67(10):1543–9. https://doi.org/10.1093/cid/ciy319 PMID: 29889239

21. Patriani D, Arguni E, Kenangalem E, Dini S, Sugiarto P, Hasanuddin A, et al. Early and late mortality after malaria in young children in Papua, Indonesia. BMC Infect Dis. 2019; 19(1):922. https://doi.org/10.1186/s12879-019-4497-y PMID: 31666012

22. Rodríguez-Morales AJ, Sánchez E, Vargas M, Piccolo C, Colina R, Arria M. Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J Trop Pediatr. 2006; 52(1):49–51. https://doi.org/10.1093/tropej/fmi069 PMID: 15980019

23. Williams TN, Maitland K, Phelps L, Bennett S, Peto TE, Viji J, et al. Plasmodium vivax: a cause of malnutrition in young children. QJM. 1997; 90(12):751–7. https://doi.org/10.1093/qjmed/90.12.751 PMID: 9536339

24. Das D, Grais RF, Okiro EA, Stepniewska K, Mansoor S, van der Kam S, et al. Complex interactions between malaria and malnutrition: a systematic literature review. BMC Med. 2018; 10(1):186. https://doi.org/10.1186/s12916-018-1177-5 PMID: 30371344

25. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012; 11:135. https://doi.org/10.1186/1475-2875-11-135 PMID: 22540175

26. White NJ. Anaemia and malaria. Malar J. 2018; 17(1):371. https://doi.org/10.1186/s12936-018-2509-9 PMID: 30340592

27. Fernando SD, Gunawardena DM, Bandara MR, De Silva D, Carter R, Mendis KN, et al. The impact of repeated malaria attacks on the school performance of children. Am J Trop Med Hyg. 2003; 69(6):582–8. PMID: 14740872

28. Fernando D, de Silva D, Carter R, Mendis KN, Wickremasinghe R. A randomized, double-blind, placebo-controlled, clinical trial of the impact of malaria prevention on the educational attainment of school children. Am J Trop Med Hyg. 2006; 74(3):386–93. PMID: 16525095
29. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007; 7(2):93–104. https://doi.org/10.1016/S1473-3099(07)70021-X PMID: 17251080

30. Moore KA, Fowkes FJI, Wiladphaingern J, Wai NS, Paw MK, Pimanpanarak M, et al. Mediation of the effect of malaria in pregnancy on stillbirth and neonatal death in an area of low transmission: observational data analysis. BMC Med. 2017; 15(1):98. https://doi.org/10.1186/s12916-017-0863-z PMID: 28486979

31. Sohail M, Shakeel S, Kumari S, Bhatti A, Zahid F, Anwar S, et al. Prevalence of Malaria Infection and Risk Factors Associated with Anaemia among Pregnant Women in Semiurban Community of Hazaribag, Jharkhand. India Biomed Res Int. 2015; 2015:740512. https://doi.org/10.1155/2015/740512 PMID: 26783526

32. Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet. 1999; 354(9178):546–9. https://doi.org/10.1016/s0140-6736(98)09247-2 PMID: 10470698

33. Bardaji A, Martínez–Espinosa FE, Arévalo–Herrera M, Padilla N, Kochar S, Ome–Kaius M, et al. Burden and impact of Plasmodium vivax in pregnancy: A multi–centre prospective observational study. PLoS Negl Trop Dis. 2017; 11(6):e0005606. https://doi.org/10.1371/journal.pntd.0005606 PMID: 28604825

34. McGready R, Lee SJ, Wiladphainge rn J, Ashley EA, Rijken MJ, Boel M, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population–based study. Lancet Infect Dis. 2012; 12(5):388–96. https://doi.org/10.1016/S1473-3099(11)70339-5 PMID: 22169409

35. Moore KA, Simpson JA, Scoullar MJL, McGready R, Fowkes FJI. Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta–analysis. Lancet Glob Health. 2017; 5(11):e1101–e12. https://doi.org/10.1016/S2214-109X(17)30340-6 PMID: 28967610

36. Moore KA, Simpson JA, Wiladph aingern J, Min AM, Pimanpanar a M, Paw MK, et al. Influence of the number and timing of malaria episodes during pregnancy on prematurity and small–for–gestational–age in an area of low transmission. BMC Med. 2017; 15(1):117. https://doi.org/10.1186/s12916-017-0877-6 PMID: 28633672

37. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, et al. Adverse pregnancy outcomes in an area where multidrug–resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008; 46(9):1374–81. https://doi.org/10.1086/586743 PMID: 18419439

38. Pincelli A, Neves PAR, Lourenco BH, Corder RM, Malta MB, Sampai o–Silva J, et al. The Hidden Burden of Plasmodium vivax Malaria in Pregnancy in the Amazon: An Observat ional Study in Northwestern Brazil. Am J Trop Med Hyg. 2018; 99(1):73–83. https://doi.org/10.4269/ajtmh.18-0135 PMID: 29741155

39. Luxembur ger C, McGready R, Kham A, Morison L, Cho T, Chongsupjaisiddhi T, et al. Effects of malaria during pregnancy on infant mortality in an area of low malaria transmission. Am J Epidemiol. 2001; 154(5):459–65. https://doi.org/10.1093/aje/154.5.459 PMID: 11532788

40. Villegas L, McGready R, Htway M, Paw MK, Pimanpanarak M, Arunjerdj a R, et al. Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double–blind, placebo–controlled trial. Trop Med Int Health. 2007; 12(2):209–18. https://doi.org/10.1111/j.1365-3156.2006.01778.x PMID: 17300627

41. McGready R, Davison BB, Stepniewska K, Cho T, Shee H, Brockman A, et al. The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hyg. 2004; 70(4):398–407. PMID: 15100454

42. Mayor A, Bardaji A, Felger I, King CL, Cistero P, Dobao C, et al. Placental infection with Plasmodium vivax: a histopathological and molecular study. J Infect Dis. 2012; 206(12):1904–10. https://doi.org/10.1093/infdis/jis614 PMID: 23053630

43. Souza RM, Ataí de R, Dombrowski JG, Ippolito V, Aitken EH, Valle SN, et al. Placental histopathological changes associated with Plasmodium vivax infection during pregnancy. PLoS Negl Trop Dis. 2013; 7(2):e2071. https://doi.org/10.1371/journal.pntd.0002071 PMID: 23459254

44. Chaikittisakul S, Rijken MJ, Muehlenbachs A, Lee SJ, Chaisi U, Viriyavejakul P, et al. A morphometric and histological study of placental malaria shows significant changes to villous architecture in both Plasmodium falciparum and Plasmodium vivax infection. Malar J. 2014; 13:4. https://doi.org/10.1186/1475-2875-13-4 PMID: 24386908

45. Chotivanich K, Udomsangpetch R, Suwanarusk R, Pukrittayakamee S, Wilairatana P, Beeson JG, et al. Plasmodium vivax adherence to placental glycosaminoglycans. PLoS ONE. 2012; 7(4):e34509. https://doi.org/10.1371/journal.pone.0034509 PMID: 22529919
46. Kochar A, Kaira P, Sb V, Ukirade V, Chahar A, Kochar DK, et al. Retinopathy of vivax malaria in adults and its relation with severity parameters. Pathog Glob Health. 2016; 110(4–5):185–93. https://doi.org/10.1080/20477724.2016.1213948 PMID: 27533797

47. Kochar SK, Kamath SD, Toshan N, Singhay Y, Kochar A. A case of Plasmodium vivax malaria presenting as acute cerebral infarct. J Vector Borne Dis. 2017; 54(2):197–200. PMID: 28748845

48. Pinzón MA, Pineda JC, Rosso F, Shinchi M, Bonilla–Abadía F. Plasmodium vivax cerebral malaria complicated with venous sinus thrombosis in Colombia. Asian Pac J Trop Med. 2013; 6(5):413–5. https://doi.org/10.1016/S1995-7645(13)60050-4 PMID: 23608385

49. Valecha N, Pinto RG, Turner GD, Kumar A, Rodrigues S, Dubhashi NG, et al. Histopathology of fatal respiratory distress caused by Plasmodium vivax malaria. Am J Trop Med Hyg. 2009; 81(5):758–62. https://doi.org/10.4269/ajtmh.2009.09-0348 PMID: 19861606

50. KDIGO. KDIGO guidelines related to the prevention or management of individuals with kidney disease. 2021. Available from: https://kdigo.org/guidelines/.

51. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical care (London, England). 2004; 8(4):R204–R12.

52. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhães BM, Siqueira AM, et al. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect Dis. 2012; 55(8):e67–74. https://doi.org/10.1093/cid/cis165 PMID: 22772803

53. Silamut K, Phu NH, Whitty C, Turner GD, Louwrier K, Mai NT, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol. 1999; 155(2):395–410. https://doi.org/10.1016/S0002-9440(10)65136-X PMID: 10433933

54. Park SY, Park YS, Park Y, Kwak YG, Song JE, Lee KS, et al. Severe vivax malaria in the Republic of Korea during the period 2000 to 2016. Travel Med Infect Dis. 2019; 30:108–13. https://doi.org/10.1016/j.tmaid.2019.04.013 PMID: 31054320

55. Purkait R, Mukherji A, Sinhamahapatra T, Bhadra R. Acute Disseminated Encephalomyelitis in a Child Following Plasmodium vivax Malaria. J Coll Physicians Surg Pak. 2015; 25(7):538–40. https://doi.org/10.7860/JCDR/2015/6914.3479 PMID: 26208563

56. Imtiaz S, Drohlia MF, Nasir K, Hussain M, Ahmad A. Morbidity and mortality associated with Plasmodium vivax and Plasmodium falciparum infection in a tertiary care kidney hospital. Saudi J Kidney Dis. 2015; 26(6):1169–76. https://doi.org/10.4103/1319-2442.168598 PMID: 26586055

57. Singh R, Kumar S, Rana SK, Thakur B, Singh SP. A comparative study of clinical profiles of vivax and falciparum malaria in children at a tertiary care centre in Uttarakhand. J Clin Diagn Res. 2013; 7(10):2234–7. https://doi.org/10.7860/JCDR/2013/6914.3479 PMID: 24298484

58. Saravu K, Rishikesh K, Kamath A, Shastry AB. Severity in Plasmodium vivax malaria claiming global vigilance and exploration—a tertiary care centre–based cohort study. Malar J. 2014; 13:304. https://doi.org/10.1186/1475-2875-13-304 PMID: 25107355

59. Nayak KC, Kumar S, Gupta BK, Kumar S, Gupta A, Prakash P, et al. Clinical and histopathological profile of acute renal failure caused by falciparum and vivax monoinfection: an observational study from Bikaner, northwest zone of Rajasthan, India. J Vector Borne Dis. 2014; 51(1):40–6. PMID: 24717201

60. Trivedi T, Bajaj P, Moulick N, Padwal N. Mortality in Malaria: Intensive Care (MIMIC). J Assoc Physicians India. 2018; 66(4):16–20. PMID: 30347945

61. Ahmad S, Shirazi N, Bhat NK, Dhar M, Mittal G, Mittal M, et al. A Hospital–Based Retrospective Comparative Study of Complications, Outcomes, Clinical and Laboratory Parameters of Malaria with and without Neurological Involvement. Mediterr J Hematol Infect Dis. 2017; 9(1):e2017006. https://doi.org/10.4084/MJHID.2017.006 PMID: 28101311

62. Siqueira AM, Lacerda MV, Magalhães BM, Mourão MP, Melo GC, Alexandre MA, et al. Characterization of Plasmodium vivax–associated admissions to reference hospitals in Brazil and India. BMC Med. 2015; 13:57. https://doi.org/10.1186/s12916-015-0302-y PMID: 25889040

63. Barber BE, William T, Grigg MJ, Piera KA, Chen Y, Wang H, et al. Nitric Oxide–Dependent Endothelial Dysfunction and Reduced Arginine Bioavailability in Plasmodium Vivax Malaria But No Greater Increase in Intravascular Hemolysis in Severe Disease. J Infect Dis. 2016; 214(10):1557–64. https://doi.org/10.1093/infdis/jiw397 PMID: 27530196

64. Ray S, Patel SK, Venkatesh A, Bhave A, Kumar V, Singh V, et al. Clinicopathological Analysis and Multipronged Quantitative Proteomics Reveal Oxidative Stress and Cytoskeletal Proteins as Possible Markers for Severe Vivax Malaria. Sci Rep. 2016; 6:24557. https://doi.org/10.1038/srep24557 PMID: 27080372
65. Anvikar AR, van Eijk AM, Shah A, Upadhyay KJ, Sullivan SA, Patel AJ, et al. Clinical and epidemiological characterization of severe Plasmodium vivax malaria in Gujarat, India. Virulence. 2020; 11(1):730–8. https://doi.org/10.1080/21505594.2020.1773107 PMID: 32490754

66. Gupta P, Sharma R, Chandra J, Kumar V, Singh R, Pande V, et al. Clinical manifestations and molecular mechanisms in the changing paradigm of vivax malaria in India. Infect Genet Evol. 2016; 39:317–24. https://doi.org/10.1016/j.meegid.2016.02.014 PMID: 26876067

67. Fernandez–Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, del Portillo HA, Gascon J. Increased expression levels of the pvcrt–o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar J. 2009; 8:55. https://doi.org/10.1186/1475-2875-8-55 PMID: 19341456

68. Melo GC, Monteiro WM, Siqueira AM, Silva SR, Magalhaes BM, Alencar AC, et al. Expression levels of pvcrt–o and pvmdr–1 are associated with chloroquine resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon. PLoS ONE. 2014; 9(8):e105922. https://doi.org/10.1371/journal.pone.0105922 PMID: 25157811

69. Yeo TW, Lampah DA, Tjitra E, Piera K, Gitawati R, Kenangalem E, et al. Greater endothelial activation, Weibel–Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum. J Infect Dis. 2010; 202(1):109–12. https://doi.org/10.1086/653211 PMID: 20497057

70. Hemmer CJ, Holst FG, Kern P, Chiwacta CB, Dietrich M, Reisinger EC. Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria. Trop Med Int Health. 2006; 11(6):817–23. https://doi.org/10.1111/j.1365-3156.2006.01635.x PMID: 16772003

71. Malaria. In: White NJ, editor. Manson’s Tropical Infectious Diseases. 23rd ed 2013.

72. Carvalho BO, Lopes SC, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, et al. On the cytoadhesion of Plasmodium vivax–infected erythrocytes. J Infect Dis. 2010; 202(4):638–47. https://doi.org/10.1086/654815 PMID: 20617923

73. Udomsanpetch R, Thanikkul K, Pukrittayakamee S, White NJ. Rosette formation by Plasmodium vivax. Trans R Soc Trop Med Hyg. 1995; 89(6):635–7. https://doi.org/10.1016/0035-9203(95)90422-0 PMID: 8594679

74. Lee WC, Malleret B, Lau YL, Mauduit M, Fong MY, Cho JS, et al. Glycophorin C (CD236R) mediates vivax malaria parasite rosetting to normocytes. Blood. 2014; 123(18):e100–9. https://doi.org/10.1182/blood-2013-12-541986

75. Barber BE, William T, Grigg MJ, Parameswaran U, Piera KA, Price RN, et al. Parasite biomass–related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog. 2015; 11(1):e1004558. https://doi.org/10.1371/journal.ppat.1004558 PMID: 25569250

76. Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, Price RN, et al. Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar–capillary inflammation. J Infect Dis. 2007; 195(4):589–96. https://doi.org/10.1086/510756 PMID: 17230420

77. De las B, Segura C, Pabón A, Lopes SC, Costa FT, Blair S. Adherence to human lung microvascular endothelial cells (HMVEC–L) of Plasmodium vivax isolates from Colombia. Malar J. 2013; 12:347. https://doi.org/10.1186/1475-2875-12-347 PMID: 24080027

78. Yamaguchi S, Kubota T, Yamagishi T, Okamoto K, Izumi T, Takada M, et al. Severe thrombocytopenia suggesting immunological mechanisms in two cases of vivax malaria. Am J Hematol. 1997; 56(3):183–6. https://doi.org/10.1002/(sici)1096-8652(199711)56:3<183::aid-ajh9>3.0.co;2-u PMID: 9371532

79. Lee SH, Looareesuwan S, Chan J, Wilairatana P, Vanijanonta S, Chong SM, et al. Plasma macrophage colony–stimulating factor and P–selectin levels in malaria–associated thrombocytopenia. Thromb Haemost. 1997; 77(2):289–93. PMID: 9157563

80. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol. 2009; 25(6):220–7. https://doi.org/10.1016/j.pt.2009.02.003 PMID: 19349210

81. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of anaemia during infection of humans with Plasmodium vivax. Am J Trop Med Hyg. 2003; 68(4):410–2. PMID: 12875288

82. Kitchen SF. The Infection of Erythrocytes by Plasmodium Vivax1. Am J Trop Med Hyg. 1938; s1–18(4):347–59.

83. Jakeman GN, Saul A, Hogarth WL, Collins WE. Anaemia of acute malaria infections in non–immune patients primarily results from destruction of uninfected erythrocytes. Parasitology. 1999; 119(Pt 2):127–33. https://doi.org/10.1017/s0031182099004564 PMID: 10466119
84. Looareesuw S, Merry AH, Phillips RE, Pleechinda R, Wattanagoon Y, Ho M, et al. Reduced erythrocyte survival following clearance of malarial parasitaemia in Thai patients. Br J Haematol. 1987; 67(4):473–8. https://doi.org/10.1111/j.1365-2141.1987.tb06171.x PMID: 3323362

85. Rivera–Correa J, Yasnott–Acosta MF, Tovar NC, Velasco–Pareja MC, Easton A, Rodriguez A. Atypical memory B–cells and autoantibodies correlate with anaemia during Plasmodium vivax complicated infections. PLoS Negl Trop Dis. 2020; 14(7):e0008466. https://doi.org/10.1371/journal.pntd.0008466 PMID: 32687495

86. World Health Organization. World malaria report 2020: 20 years of global progress and challenges. Geneva, Switzerland; 2020.

87. Langer EF, Magalhães BM, Vitor–Silva S, Siqueira AM, Benzecry SG, Alexandre MA, et al. Risk factors and characterization of Plasmodium vivax–associated admissions to pediatric intensive care units in the Brazilian Amazon. PLoS ONE. 2012; 7(4):e35406. https://doi.org/10.1371/journal.pone.0035406 PMID: 22523591

88. Kenangalem E, Poespoprodjo JR, Douglas NM, Burdam FH, Gdeumana K, Chalfein F, et al. Malaria morbidity and mortality following introduction of a universal policy of artemisinin–based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLoS Med. 2019; 16(5):e1002815. https://doi.org/10.1371/journal.pmed.1002815 PMID: 31167228

89. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugianto P, Plumb ID, et al. The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. BMC Med. 2014; 12:217. https://doi.org/10.1186/s12916-014-0217-z PMID: 25406857

90. White NJ. The rise and fall of long–latency Plasmodium vivax. Trans R Soc Trop Med Hyg. 2019; 113(4):163–8. https://doi.org/10.1093/trstmh/trz002 PMID: 30809676

91. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN. On the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malar J. 2018; 17(1):346. https://doi.org/10.1186/s12936-018-2495-y PMID: 30286752

92. Douglas NM, Pontororing GJ, Lampah DA, Yeo TW, Kenangalem E, Poespoprodjo JR, et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua. Indonesia BMC Med. 2014; 22:217. https://doi.org/10.1186/s12916-014-0217-z PMID: 25406857

93. Bhattacharya SK, Sur D, Dutta S, Kanungo S, Ochiai RL, Kim DR, et al. Vivax malaria and bacteremia: a prospective study in Kolkata. India Malar J. 2013; 12:176. https://doi.org/10.1186/1475-2875-12-176 PMID: 23721247

94. Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W. Severe vivax malaria: a systematic review and meta–analysis of clinical studies since 1900. Malar J. 2014; 13:481. https://doi.org/10.1186/1475-2875-13-481 PMID: 25469908

95. Taylor WRJ, Hanson J, Turner GDH, White NJ, Dondorp AM. Respiratory manifestations of malaria. Chest. 2012; 142(2):492–505. https://doi.org/10.1378/chest.11-2655 PMID: 22871759

96. Price L, Planche T, Rayner C, Krishna S. Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Trans R Soc Trop Med Hyg. 2007; 101(7):655–9. https://doi.org/10.1016/j.trstmh.2007.02.014 PMID: 17433898

97. Lacerda MV, Mourão MP, Coelho HC, Santos JB. Thrombocytopenia in malaria: who cares? Mem Inst Oswaldo Cruz. 2011; 106(Suppl 1):52–63. https://doi.org/10.1590/s0074-027620110000900007 PMID: 21861757

98. Lampah DA, Yeo TW, Malloy M, Kenangalem E, Douglas NM, Ronaldo D, et al. Severe malarial thrombocytopenia: a risk factor for mortality in Papua. Indonesia J Infect Dis 2015; 211(4):623–34. https://doi.org/10.1093/infdis/jiu487 PMID: 25170106

99. Watson JA, Ndila CM, Uyoga S, Macharia A, Nyutu G, Mohammed S, et al. Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision. Elife. 2021; 10. https://doi.org/10.7554/eLife.69698 PMID: 34225842

100. Lacerda MV, Mourão MP, Alexandre MA, Siqueira AM, Magalhães BM, Martinez–Espinosa FE, et al. Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature. Malar J. 2012; 11:12. https://doi.org/10.1186/1475-2875-11-12 PMID: 22230294

101. Naing C, Whittaker MA, Nyunt Wai V, Mak JW. Is Plasmodium vivax malaria a severe malaria?: a systematic review and meta–analysis. PLoS Negl Trop Dis. 2014; 8(8):e3071. https://doi.org/10.1371/journal.pntd.0003071 PMID: 25121491

102. Thriemer K, Ley B, von Seidefeld L. Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure. PLoS Med. 2021; 18(4):e1003494. https://doi.org/10.1371/journal.pmed.1003494 PMID: 33891589
103. Saito M, Briand V, Min AM, McGready R. Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs. Lancet Child Adolesc Health. 2020; 4(10):761–74. https://doi.org/10.1016/S2352-4642(20)30099-7 PMID: 32946830